Novartis' Kymriah is the first gene therapy approved by the FDA.
The treatment is the first of its kind to be authorized in the U.S.
Jim Cramer is bullish on Novartis AG, Sirius XM Radio, Coupa Software and Juno Therapeutics.
Jim Cramer says the calendar and the momentum holders are coalescing to produce selling. Here's what investors should do about it.